BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
Number Citing Articles
1 Iliopoulou L, Kollias G. Harnessing murine models of Crohn's disease ileitis to advance concepts of pathophysiology and treatment. Mucosal Immunol 2021. [PMID: 34316007 DOI: 10.1038/s41385-021-00433-3] [Reference Citation Analysis]
2 Yang QY, Liu YJ, Xu Y, Zhang L, Wang CD. Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease. J Dig Dis 2021;22:473-80. [PMID: 34240823 DOI: 10.1111/1751-2980.13032] [Reference Citation Analysis]
3 An YK. Common mistakes with steroids. J Gastroenterol Hepatol 2021;36 Suppl 1:30-1. [PMID: 33817842 DOI: 10.1111/jgh.15458] [Reference Citation Analysis]
4 Labriola F, Marcato C, Zarbo C, Betti L, Catelli A, Valerii MC, Spisni E, Alvisi P. Dietary Habits of a Group of Children with Crohn’s Disease Compared to Healthy Subjects: Assessment of Risk of Nutritional Deficiencies through a Bromatological Analysis. Nutrients 2022;14:499. [DOI: 10.3390/nu14030499] [Reference Citation Analysis]
5 Xia SL, Min QJ, Shao XX, Lin DP, Ma GL, Wu H, Cao SG, Jiang Y. Influence of Vitamin D3 Supplementation on Infliximab Effectiveness in Chinese Patients With Crohn's Disease: A Retrospective Cohort Study. Front Nutr 2021;8:739285. [PMID: 34746207 DOI: 10.3389/fnut.2021.739285] [Reference Citation Analysis]
6 Zhang W, Michalowski CB, Beloqui A. Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. Front Bioeng Biotechnol 2021;9:675194. [PMID: 34150733 DOI: 10.3389/fbioe.2021.675194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sagar R, Lenti MV, Clark T, Rafferty HJ, Gracie DJ, Ford AC, O'Connor A, Ahmad T, Hamlin PJ, Selinger CP. Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. Inflamm Intest Dis 2021;6:132-9. [PMID: 34722643 DOI: 10.1159/000515593] [Reference Citation Analysis]
8 Adamina M, Feakins R, Iacucci M, Spinelli A, Cannatelli R, D'Hoore A, Driessen A, Katsanos K, Mookhoek A, Myrelid P, Pellino G, Peros G, Tontini GE, Tripathi M, Yanai H, Svrcek M. ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology. J Crohns Colitis 2021;15:1089-105. [PMID: 33428711 DOI: 10.1093/ecco-jcc/jjab011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Sinopoulou V, Gordon M, Dovey TM, Akobeng AK. Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst Rev 2021;7:CD013589. [PMID: 34291816 DOI: 10.1002/14651858.CD013589.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Drosos AA, Pelechas E, Voulgari PV. Treatment strategies of Covid-19. A rheumatology perspective. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.014] [Reference Citation Analysis]
11 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
12 Khan N, Wang L, Trivedi C, Pernes T, Patel M, Xie D, Yang YX. Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00754-0. [PMID: 34274513 DOI: 10.1016/j.cgh.2021.07.023] [Reference Citation Analysis]
13 Selinger CP. Biologicals are the main contributor to cost of care for IBD: a European perspective. Lancet Gastroenterol Hepatol 2020;5:421-2. [PMID: 32061323 DOI: 10.1016/S2468-1253(20)30042-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Torun A, Hupalowska A, Trzonkowski P, Kierkus J, Pyrzynska B. Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children. Front Immunol 2021;12:642166. [PMID: 34163468 DOI: 10.3389/fimmu.2021.642166] [Reference Citation Analysis]
15 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
17 Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA, Walker GJ; PROTECT ASUC collaborators. Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterol 2022;9:e000763. [DOI: 10.1136/bmjgast-2021-000763] [Reference Citation Analysis]
18 Cainzos-Achirica M, Glassner K, Zawahir HS, Dey AK, Agrawal T, Quigley EMM, Abraham BP, Acquah I, Yahya T, Mehta NN, Nasir K. Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2020;76:2895-905. [PMID: 33303079 DOI: 10.1016/j.jacc.2020.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel) 2020;11:E1212. [PMID: 33081236 DOI: 10.3390/genes11101212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 de Bock E, Filipe MD, Meij V, Oldenburg B, van Schaik FDM, Bastian OW, Fidder HF, Vriens MR, Richir MC. Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands. BMJ Open Gastroenterol 2021;8:e000670. [PMID: 34215570 DOI: 10.1136/bmjgast-2021-000670] [Reference Citation Analysis]
21 Tang-Fichaux M, Chagneau CV, Bossuet-Greif N, Nougayrède JP, Oswald É, Branchu P. The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin. mSphere 2020;5:e01195-20. [PMID: 33328353 DOI: 10.1128/mSphere.01195-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
22 Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, Probert C, Fraser A, Cheshire A, Lewis A, Sugrue K, Laird S, Scott G. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond) 2021;82:1-11. [PMID: 34726945 DOI: 10.12968/hmed.2021.0399] [Reference Citation Analysis]
23 Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020;5:525. [PMID: 32220656 DOI: 10.1016/s2468-1253(20)30085-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
24 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Inagaki Y, Azuma K, Nakamura Y, Kouno S, Matsuda Y, Atagi S. Meaningful Symptoms of Immune Checkpoint Inhibitor Therapy-Related Gastrointestinal Adverse Events in Patients With Inflammatory Bowel Disease. J Clin Oncol 2020;38:1748-9. [PMID: 32250716 DOI: 10.1200/JCO.20.00033] [Reference Citation Analysis]
26 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Reference Citation Analysis]
27 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
28 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
29 Lovatt J, Gascoyne-Binzi D, Hussey T, Garside M, McGill F, Selinger CP. Screening for TB in Hospitalised Patients with Inflammatory Bowel Disease before Anti-TNF Therapy: Is QuantiFERON® Gold Testing Useful? J Clin Med 2021;10:1816. [PMID: 33919426 DOI: 10.3390/jcm10091816] [Reference Citation Analysis]
30 Patel M, Gulati S, Iqbal F, Hayee B. Rapid development of accurate artificial intelligence scoring for colitis disease activity using applied data science techniques. Endosc Int Open 2022;10:E539-43. [DOI: 10.1055/a-1790-6201] [Reference Citation Analysis]
31 Doherty J, Fennessy S, Stack R, O' Morain N, Cullen G, Ryan EJ, De Gascun C, Doherty GA. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021;54:1110-23. [PMID: 34472643 DOI: 10.1111/apt.16590] [Reference Citation Analysis]
32 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Reference Citation Analysis]
33 Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984-90. [PMID: 32303607 DOI: 10.1136/gutjnl-2020-321244] [Cited by in Crossref: 124] [Cited by in F6Publishing: 114] [Article Influence: 62.0] [Reference Citation Analysis]
34 Erdman KA, Jones KW, Madden RF, Gammack N, Parnell JA. Dietary Patterns in Runners with Gastrointestinal Disorders. Nutrients 2021;13:448. [PMID: 33572891 DOI: 10.3390/nu13020448] [Reference Citation Analysis]
35 Lemay JA, Yamamoto M, Kroezen Z, Shanmuganathan M, Ly R, Hart L, Pai N, Britz-McKibbin P. Lyophilized fecal short-chain fatty acid and electrolyte determination by capillary electrophoresis with indirect UV detection for assessment of pediatric inflammatory bowel disease. J Pharm Biomed Anal 2021;192:113658. [PMID: 33091761 DOI: 10.1016/j.jpba.2020.113658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wen Y, Niu J, Zhang F, Wu J, Li M, Sun Y, Wang W, Xia S, Tan Y, Wang K, Miao Y. Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis. Scand J Gastroenterol 2020;55:677-86. [PMID: 32538201 DOI: 10.1080/00365521.2020.1774924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rodriguez-Palacios A, Basson AR, Cominelli F. Artificial Sweeteners and Whole-Food Science: Could Mice Help Clinicians Make Diet Recommendations for IBD Patients? Gastroenterology 2021;161:8-14. [PMID: 33798527 DOI: 10.1053/j.gastro.2021.03.041] [Reference Citation Analysis]
39 Tontini GE, Rimondi A, Vernero M, Neumann H, Vecchi M, Bezzio C, Cavallaro F. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. Therap Adv Gastroenterol 2021;14:17562848211017730. [PMID: 34178115 DOI: 10.1177/17562848211017730] [Reference Citation Analysis]
40 Huang Q, Zhang X, Hu Z. Application of Artificial Intelligence Modeling Technology Based on Multi-Omics in Noninvasive Diagnosis of Inflammatory Bowel Disease. J Inflamm Res 2021;14:1933-43. [PMID: 34017190 DOI: 10.2147/JIR.S306816] [Reference Citation Analysis]
41 Day AS, Yao CK, Costello SP, Andrews JM, Bryant RV. Food avoidance, restrictive eating behaviour and association with quality of life in adults with inflammatory bowel disease: A systematic scoping review. Appetite 2021;167:105650. [PMID: 34391842 DOI: 10.1016/j.appet.2021.105650] [Reference Citation Analysis]
42 Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, Goodhand J. Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterol 2021;12:461-70. [PMID: 34712463 DOI: 10.1136/flgastro-2019-101369] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Greer MC, Cytter-Kuint R, Pratt LT, Soboleski D, Focht G, Castro DA. Clinical-stage Approaches for Imaging Chronic Inflammation and Fibrosis in Crohn's Disease. Inflamm Bowel Dis 2020;26:1509-23. [PMID: 32946578 DOI: 10.1093/ibd/izaa218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. [PMID: 32595762 DOI: 10.1177/1756284820934626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
45 Fantini MC, Guadagni I. From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. Dig Liver Dis 2021;53:558-65. [PMID: 33541800 DOI: 10.1016/j.dld.2021.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
46 Polidano K, Chew-Graham CA, Farmer AD, Saunders B. Access to Psychological Support for Young People Following Stoma Surgery: Exploring Patients' and Clinicians' Perspectives. Qual Health Res 2021;31:535-49. [PMID: 33228473 DOI: 10.1177/1049732320972338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Forbes A. Immunosuppressants and immune modulators in luminal gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101759. [PMID: 34874843 DOI: 10.1016/j.bpg.2021.101759] [Reference Citation Analysis]
48 Zand A, Shi S, Nguyen D, Kim B, Esrailian E, Hommes D. Recall of Care Objectives by Patients with Inflammatory Bowel Diseases. Gastrointestinal Disorders 2022;4:49-55. [DOI: 10.3390/gidisord4010006] [Reference Citation Analysis]
49 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
51 Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators., UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
52 Brar MS, de Buck van Overstraeten A, Baxter NN. Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study. J Crohns Colitis 2021:jjab090. [PMID: 34165532 DOI: 10.1093/ecco-jcc/jjab090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Martínez V, Iriondo De-Hond A, Borrelli F, Capasso R, Del Castillo MD, Abalo R. Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals? Int J Mol Sci 2020;21:E3067. [PMID: 32357565 DOI: 10.3390/ijms21093067] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
54 Gadsby J, Hall K, Shah F, Pattni S, Gethins S, Mulla H. Infliximab: a single-centre, prospective, observational evaluation of TDM data in patients with IBD. Eur J Hosp Pharm 2022:ejhpharm-2021-003015. [PMID: 35217509 DOI: 10.1136/ejhpharm-2021-003015] [Reference Citation Analysis]
55 Edwards K, Yearsley K. Unusual presentation of Crohn's disease. BMJ Case Rep 2021;14:e242703. [PMID: 34108157 DOI: 10.1136/bcr-2021-242703] [Reference Citation Analysis]
56 Gorrepati VS, Soriano C, Johri A, Dalessio S, Stuart A, Koltun W, Tinsley A, Clarke K, Williams E, Coates M. Abdominal Pain and Anxious or Depressed State Are Independently Associated With Weight Loss in Inflammatory Bowel Disease. Crohns Colitis 360 2020;2:otaa047. [PMID: 32671337 DOI: 10.1093/crocol/otaa047] [Reference Citation Analysis]
57 Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res 2020;161:105206. [PMID: 32998068 DOI: 10.1016/j.phrs.2020.105206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Maclean A, Ashton JJ, Garrick V, Beattie RM, Hansen R. Impact of COVID-19 on the diagnosis, assessment and management of children with inflammatory bowel disease in the UK: implications for practice. BMJ Paediatr Open 2020;4:e000786. [PMID: 34192173 DOI: 10.1136/bmjpo-2020-000786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Fumery M, Yzet C, Chatelain D, Yzet T, Brazier F, LeMouel JP, Laharie D, Sabbagh C. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management. J Crohns Colitis 2021:jjab068. [PMID: 33844013 DOI: 10.1093/ecco-jcc/jjab068] [Reference Citation Analysis]
60 Orieux A, Brunier J, Rigothier C, Pinson B, Dabernat S, Bats ML. Plasma creatinine below limit of quantification in a patient with acute kidney injury. Clin Chim Acta 2022;524:101-5. [PMID: 34883091 DOI: 10.1016/j.cca.2021.12.001] [Reference Citation Analysis]
61 Hicks A, Hamlin PJ, Selinger CP. The Association of Introducing a Faecal Calprotectin Testing Pathway for Suspected Inflammatory Bowel Disease in Primary Care and Time to Diagnosis or Treatment. Inflamm Intest Dis 2020;5:191-9. [PMID: 33313071 DOI: 10.1159/000509907] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Pouw RE, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1261-73. [PMID: 34715702 DOI: 10.1055/a-1671-6336] [Reference Citation Analysis]
63 Joustra V, Duijvestein M, Mookhoek A, Bemelman W, Buskens C, Koželj M, Novak G, Hindryckx P, Mostafavi N, D'Haens G. Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study. Inflamm Bowel Dis 2021:izab044. [PMID: 33783507 DOI: 10.1093/ibd/izab044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2021:S0016-5085(21)03707-0. [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035] [Reference Citation Analysis]
65 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
66 Loras C, Mañosa M, Andújar X, Sánchiz V, Martí-Gallostra M, Zabana Y, Gutiérrez A, Barreiro-de Acosta M; en representación de GETECCU. Position Statement. Recommendations of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn's disease. Gastroenterol Hepatol 2021:S0210-5705(21)00219-3. [PMID: 34274357 DOI: 10.1016/j.gastrohep.2021.07.001] [Reference Citation Analysis]
67 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications? Nutrients 2021;13:4036. [PMID: 34836291 DOI: 10.3390/nu13114036] [Reference Citation Analysis]
68 Mitrev N, Huang H, Hannah B, Kariyawasam VC. Review of exclusive enteral therapy in adult Crohn's disease. BMJ Open Gastroenterol 2021;8:e000745. [PMID: 34580154 DOI: 10.1136/bmjgast-2021-000745] [Reference Citation Analysis]
69 Yalchin M, Baker AM, Graham TA, Hart A. Predicting Colorectal Cancer Occurrence in IBD. Cancers (Basel) 2021;13:2908. [PMID: 34200768 DOI: 10.3390/cancers13122908] [Reference Citation Analysis]
70 Yao J, Jiang X, You JHS. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy. Inflamm Bowel Dis 2021;27:275-82. [PMID: 32311018 DOI: 10.1093/ibd/izaa073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
71 Yusuf F, Kamarlis RK, Muhsin M. Ulcerative Colitis in Hemophilia A Patient: Case Report. Mater Sociomed 2021;33:75-7. [PMID: 34012356 DOI: 10.5455/msm.2021.33.75-77] [Reference Citation Analysis]
72 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Basson AR, Rodriguez-Palacios A, Cominelli F. Artificial Sweeteners: History and New Concepts on Inflammation. Front Nutr 2021;8:746247. [PMID: 34631773 DOI: 10.3389/fnut.2021.746247] [Reference Citation Analysis]
74 Roblin X, Genin C, Nancey S, Williet N, Veyrard P, Boschetti G, Phelip JM, Berger AE, Killian M, Waeckel L, Flourie B, Paul S. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels. Inflamm Bowel Dis 2021:izab158. [PMID: 34405867 DOI: 10.1093/ibd/izab158] [Reference Citation Analysis]
75 Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, Kennedy U, Byrne K, Egan LJ, McKiernan S, MacCarthy F, Sengupta S, Sheridan J, Mulcahy HE, Cullen G, Slattery E, Kevans D, Doherty GA. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol 2020;11:441-7. [PMID: 33104766 DOI: 10.1136/flgastro-2019-101335] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endocr Rev 2021:bnab028. [PMID: 34476488 DOI: 10.1210/endrev/bnab028] [Reference Citation Analysis]
77 Cohan JN, Ozanne EM, Hofer RK, Kelly YM, Kata A, Larsen C, Finlayson E. Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. BMC Gastroenterol 2021;21:347. [PMID: 34538236 DOI: 10.1186/s12876-021-01916-0] [Reference Citation Analysis]
78 Chiarello MM, Pepe G, Fico V, Bianchi V, Tropeano G, Altieri G, Brisinda G. Therapeutic strategies in Crohn’s disease in an emergency surgical setting. World J Gastroenterol 2022; 28(18): 1902-1921 [DOI: 10.3748/wjg.v28.i18.1902] [Reference Citation Analysis]
79 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Reference Citation Analysis]
81 Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW, Kim JH, Kim YJ. Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 2020;13:1756284820961302. [PMID: 33029199 DOI: 10.1177/1756284820961302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Sinopoulou V, Gordon M, Limketkai BN, Mullin G, Aali G, Akobeng AK; Cochrane Gut Group. Prebiotics for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015084] [Reference Citation Analysis]
83 Kumar A, Al-hassi HO, Steed H, Phipps O, Brookes MJ, Nakamura M. Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/8416578] [Reference Citation Analysis]
84 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
85 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
86 Jain SR, Ow ZGW, Chin YH, Lim WH, Kong G, Tham HY, Wong NW, Chong CS, Foo FJ, Chan WPW. Quantifying the rate of recurrence of postoperative Crohn's disease with biological therapy. A meta-analysis. J Dig Dis 2021;22:399-407. [PMID: 34048153 DOI: 10.1111/1751-2980.13025] [Reference Citation Analysis]
87 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Chandwe K, Kelly P. Colostrum Therapy for Human Gastrointestinal Health and Disease. Nutrients 2021;13:1956. [PMID: 34200282 DOI: 10.3390/nu13061956] [Reference Citation Analysis]
89 Burisch J, Bergemalm D, Halfvarson J, Domislovic V, Krznaric Z, Goldis A, Dahlerup JF, Oksanen P, Collin P, de Castro L, Hernandez V, Turcan S, Belousova E, D'Incà R, Sartini A, Valpiani D, Giannotta M, Misra R, Arebi N, Duricova D, Bortlik M, Gatt K, Ellul P, Pedersen N, Kjeldsen J, Andersen KW, Andersen V, Katsanos KH, Christodoulou DK, Sebastian S, Barros L, Magro F, Midjord JM, Nielsen KR, Salupere R, Kievit HA, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Kaimakliotis IP, Schwartz D, Odes S, Lakatos L, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United European Gastroenterol J 2020;8:949-60. [PMID: 32715989 DOI: 10.1177/2050640620945949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
90 Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:38-45. [PMID: 33284639 DOI: 10.1080/00365521.2020.1854342] [Reference Citation Analysis]
91 Shields VE, Cooper J. Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review. Parasitology 2021;:1-10. [PMID: 34579797 DOI: 10.1017/S0031182021001670] [Reference Citation Analysis]
92 Patel RN, Nigam GB, Jatale RG, Desai D, Makharia G, Ahuja V, Limdi JK. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol 2020;39:176-85. [PMID: 32483692 DOI: 10.1007/s12664-020-01047-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
94 Lamot L, Miler M, Vukojević R, Vidović M, Lamot M, Trutin I, Gabaj NN, Harjaček M. The Increased Levels of Fecal Calprotectin in Children With Active Enthesitis Related Arthritis and MRI Signs of Sacroiliitis: The Results of a Single Center Cross-Sectional Exploratory Study in Juvenile Idiopathic Arthritis Patients. Front Med (Lausanne) 2021;8:650619. [PMID: 33763437 DOI: 10.3389/fmed.2021.650619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol 2021;18:101-16. [PMID: 33208922 DOI: 10.1038/s41575-020-00375-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
96 Richard L, Noller G, Derrett S, Sullivan T, Doolan-Noble F, McCombie A, Schultz M, Ho C, Stokes T. Patients' accounts of living with and managing inflammatory bowel disease in rural Southern New Zealand: a qualitative study. BMJ Open 2020;10:e041789. [PMID: 33184085 DOI: 10.1136/bmjopen-2020-041789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
98 Quera R, Simian D, Núñez P, Flores L, Figueroa C, Ibáñez P, Kronberg U, Lubascher J, Pizarro G. Are patients with inflammatory bowel disease receiving adequate immunisation? Gastroenterol Hepatol 2021;44:198-205. [PMID: 33131901 DOI: 10.1016/j.gastrohep.2020.06.024] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scandinavian Journal of Gastroenterology 2020;55:920-3. [DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Ahmed S, Newton PD, Ojo O, Dibley L. Experiences of ethnic minority patients who are living with a primary chronic bowel condition: a systematic scoping review with narrative synthesis. BMC Gastroenterol 2021;21:322. [PMID: 34407752 DOI: 10.1186/s12876-021-01857-8] [Reference Citation Analysis]
101 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, Ciccone A, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol 2022;22:92. [PMID: 35240984 DOI: 10.1186/s12876-022-02157-5] [Reference Citation Analysis]
103 Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31281-7. [PMID: 32931960 DOI: 10.1016/j.cgh.2020.09.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
104 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 23.5] [Reference Citation Analysis]
105 Chaparro M, Donday MG, Abad-Santos F, Martín de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol 2021;14:17562848211018097. [PMID: 34158835 DOI: 10.1177/17562848211018097] [Reference Citation Analysis]
106 Li Z, Wang Y, Liu J, Rawding P, Bu J, Hong S, Hu Q. Chemically and Biologically Engineered Bacteria-Based Delivery Systems for Emerging Diagnosis and Advanced Therapy. Adv Mater 2021;:e2102580. [PMID: 34347325 DOI: 10.1002/adma.202102580] [Reference Citation Analysis]
107 Pérez-Garza DM, Chavez-Alvarez S, Ocampo-Candiani J, Gomez-Flores M. Erythema Nodosum: A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 2021;22:367-78. [PMID: 33683567 DOI: 10.1007/s40257-021-00592-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Yang D, Li Y, Sun H, He C, Chen G, Zhao Z, Tang T, M'koma A. A Study on Differences between Professional Endoscopists and Gastroenterologists in Endoscopic Detection and Standard Pathological Biopsy of Inflammatory Bowel Diseases. Gastroenterology Research and Practice 2022;2022:1-8. [DOI: 10.1155/2022/7333579] [Reference Citation Analysis]
109 Frigerio S, Lartey DA, D'Haens GR, Grootjans J. The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms. Int J Mol Sci 2021;22:12739. [PMID: 34884543 DOI: 10.3390/ijms222312739] [Reference Citation Analysis]
110 Corridoni D, Chapman T, Antanaviciute A, Satsangi J, Simmons A. Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies. Inflammatory Bowel Diseases 2020;26:1658-68. [DOI: 10.1093/ibd/izaa089] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
111 Si Y, Shao L, Gao S, Wen H. Suppository treatment in ulcerative proctitis. Eur J Inflamm 2021;19:205873922110151. [DOI: 10.1177/20587392211015108] [Reference Citation Analysis]
112 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Reference Citation Analysis]
113 Naseer M, Poola S, Dailey FE, Akin H, Tahan V. Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. World J Meta-Anal 2020; 8(5): 383-399 [DOI: 10.13105/wjma.v8.i5.383] [Reference Citation Analysis]
114 Wong NACS, Wallage MJ, Virgo P, Lowes H. Sampling endoscopically normal large bowel mucosa from patients presenting with elevated faecal calprotectin levels is not clinically justified. J Clin Pathol 2021:jclinpath-2020-207343. [PMID: 33509947 DOI: 10.1136/jclinpath-2020-207343] [Reference Citation Analysis]
115 Miller C, Emmanuel A, Zarate-Lopez N, Taylor S, Bloom S. Constipation in ulcerative colitis: pathophysiology and practical management. Frontline Gastroenterol 2021;12:493-9. [PMID: 34712467 DOI: 10.1136/flgastro-2020-101566] [Reference Citation Analysis]
116 Radford SJ, Taylor S, Moran G. Ultrasound use to assess Crohn’s disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102065] [Reference Citation Analysis]
117 Snook J, Bhala N, Beales ILP, Cannings D, Kightley C, Logan RP, Pritchard DM, Sidhu R, Surgenor S, Thomas W, Verma AM, Goddard AF. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut 2021;70:2030-51. [PMID: 34497146 DOI: 10.1136/gutjnl-2021-325210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00267-X. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Wall CL, McCombie A, Mulder R, Day AS, Gearry RB. Adherence to exclusive enteral nutrition by adults with active Crohn's disease is associated with conscientiousness personality trait: a sub-study. J Hum Nutr Diet 2020;33:752-7. [PMID: 32627898 DOI: 10.1111/jhn.12787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Weissman S, Systrom HK, Aziz M, El-Dallal M, Lee-Smith W, Sciarra M, Feuerstein JD. Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. Inflamm Bowel Dis 2021:izab164. [PMID: 34245270 DOI: 10.1093/ibd/izab164] [Reference Citation Analysis]
121 Uchino M, Ikeuchi H, Hata K, Minagawa T, Horio Y, Kuwahara R, Nakamura S, Watanabe K, Saruta M, Fujii T, Kobayashi T, Sugimoto K, Hirai F, Esaki M, Hiraoka S, Matsuoka K, Shinzaki S, Matsuura M, Inoue N, Nakase H, Watanabe M. Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:864-72. [PMID: 33002235 DOI: 10.1111/jgh.15288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, Bartkowiak-Wieczorek J, Mądry E. High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review. Cells 2021;10:3164. [PMID: 34831387 DOI: 10.3390/cells10113164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, Manship TA, Jagger FAM, Brindle WM, Shivakumar M, Satsangi J, Arnott IDR. The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflamm Bowel Dis 2021;27:451-7. [PMID: 32572468 DOI: 10.1093/ibd/izaa088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
124 Neumann H, Emura F, Bokemeyer B, Guda N, Tajiri H, Matsumoto T, Rubin DT. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc. 2020;32:658-662. [PMID: 32369646 DOI: 10.1111/den.13712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
125 Bertani L, Tricò D, Zanzi F, Baiano Svizzero G, Coppini F, de Bortoli N, Bellini M, Antonioli L, Blandizzi C, Marchi S. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. Nutrients 2021;13:608. [PMID: 33673371 DOI: 10.3390/nu13020608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
126 Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG; GALAXI-1 Investigators. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology 2022:S0016-5085(22)00102-0. [PMID: 35134323 DOI: 10.1053/j.gastro.2022.01.047] [Reference Citation Analysis]
127 Johnson LE, Lee MJ, Turner-Moore T, Grinsted Tate LR, Brooks AJ, Tattersall RS, Jones GL, Lobo AJ. Systematic Review of Factors Affecting Transition Readiness Skills in Patients with Inflammatory Bowel Disease. J Crohns Colitis 2021;15:1049-59. [PMID: 33252669 DOI: 10.1093/ecco-jcc/jjaa245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Nelson A, Stewart CJ, Kennedy NA, Lodge JK, Tremelling M, Probert CS, Parkes M, Mansfield JC, Smith DL, Hold GL, Lees CW, Bridge SH, Lamb CA; UK IBD Genetics Consortium. The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. J Crohns Colitis 2021;15:800-12. [PMID: 33119074 DOI: 10.1093/ecco-jcc/jjaa220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Matsuoka K. NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res 2020;18:275-81. [PMID: 32482022 DOI: 10.5217/ir.2020.00002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
130 Bakshi N, Hart AL, Lee MC, Williams ACC, Lackner JM, Norton C, Croft P. Chronic pain in patients with inflammatory bowel disease. Pain 2021;162:2466-71. [PMID: 34534174 DOI: 10.1097/j.pain.0000000000002304] [Reference Citation Analysis]
131 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
132 Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R, Watanabe M, Tsuchiya K. Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells. J Crohns Colitis 2021:jjab115. [PMID: 34180971 DOI: 10.1093/ecco-jcc/jjab115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
135 Segal JP, Htet HMT, Limdi J, Hayee B. How to manage IBD in the 'elderly'. Frontline Gastroenterol 2020;11:468-77. [PMID: 33101625 DOI: 10.1136/flgastro-2019-101218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Yang Q, Chen L, Feng L, Liu C, Fang L, Liu Z, Sun X. Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis. Inflamm Bowel Dis 2021:izab181. [PMID: 34398196 DOI: 10.1093/ibd/izab181] [Reference Citation Analysis]
137 Phisalprapa P, Kositamongkol C, Limsrivilai J, Aniwan S, Charatcharoenwitthaya P, Pisespongsa P, Kitiyakara T, Treepongkaruna S, Chaiyakunapruk N. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand. J Med Econ 2020;23:1302-10. [PMID: 32729347 DOI: 10.1080/13696998.2020.1803889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Hou S, Yang X, Tong Y, Yang Y, Chen Q, Wan B, Wei R, Wang Y, Zhang Y, Kong B, Huang J, Chen Y, Lu T, Hu Q, Du D. Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis. Eur J Med Chem 2021;211:113114. [PMID: 33360793 DOI: 10.1016/j.ejmech.2020.113114] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
140 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
141 Bourchany A, Gilletta De Saint-Joseph C, Breton A, Barreau F, Mas E. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Curr Opin Pharmacol 2020;54:51-8. [PMID: 32947075 DOI: 10.1016/j.coph.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Halliday G, Porter RJ, Black CJ, Arends MJ, Din S. c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions. World J Gastroenterol 2022; 28(13): 1338-1346 [DOI: 10.3748/wjg.v28.i13.1338] [Reference Citation Analysis]
143 Smith PJ. Moving house-moving medical teams: keeping control of my IBD. Frontline Gastroenterol 2021;12:3-4. [PMID: 33493245 DOI: 10.1136/flgastro-2019-101378] [Reference Citation Analysis]
144 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Reference Citation Analysis]
145 Kabir M, Thomas-Gibson S, Hart AL, Wilson A. Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace results of an international clinician survey. J Crohns Colitis 2021:jjab110. [PMID: 34155511 DOI: 10.1093/ecco-jcc/jjab110] [Reference Citation Analysis]
146 Vespa E, Furfaro F, Allocca M, Fiorino G, Correale C, Gilardi D, Argollo M, Zilli A, Zacharopoulou E, Loy L, Danese S. Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. Expert Rev Gastroenterol Hepatol 2020;14:829-41. [PMID: 32758015 DOI: 10.1080/17474124.2020.1807325] [Reference Citation Analysis]
147 Zhang T, Xu Y, Yao Y, Jin L, Liu H, Zhou Y, Gu L, Ji Q, Zhu W, Gong J. Randomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab065. [PMID: 33749741 DOI: 10.1093/ibd/izab065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Tun GSZ, Robinson K, Marshall L, Wright A, Thompson L, Wild G, Sargur R, Brooks AJ, Hale MF, Chew TS, Lobo AJ. The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab. Eur J Gastroenterol Hepatol 2022;34:295-301. [PMID: 35100176 DOI: 10.1097/MEG.0000000000002289] [Reference Citation Analysis]
150 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Reference Citation Analysis]
151 Napolitano D, Scaldaferri F, Fiorino G, Spagnuolo R, Leonetti A, Lopetuso LR, Cocchieri A. Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. Gastroenterol Nurs 2021;44:E59-66. [PMID: 34037573 DOI: 10.1097/SGA.0000000000000593] [Reference Citation Analysis]
152 Beute J, Boermans P, KleinJan A. Evaluation of Real-Life Investigational Use of Enoximone in Asthma, the Third Step in Drug Repurposing: A Preliminary Report. Can Respir J 2021;2021:7456208. [PMID: 34760031 DOI: 10.1155/2021/7456208] [Reference Citation Analysis]
153 Deng F, Xia P, Wu Z, Zhou H, Wang X. Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn's Disease. Int J Gen Med 2021;14:3387-96. [PMID: 34285563 DOI: 10.2147/IJGM.S315505] [Reference Citation Analysis]
154 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Reference Citation Analysis]
155 Gordon C, Chee D, Hamilton B, Heerasing NM, Hendy P, Chanchlani N, Lin S, Wesley E, Daniels IR, Silva N, Osborne M, Kennedy NA, Goodhand JR, Ahmad T. Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:291-301. [PMID: 33159472 DOI: 10.1111/apt.16155] [Reference Citation Analysis]
156 Chen S, Zhang C, He B, He R, Xu L, Zhang S. The Role of lncRNAs in Regulating the Intestinal Mucosal Mechanical Barrier. Biomed Res Int 2021;2021:2294942. [PMID: 34820453 DOI: 10.1155/2021/2294942] [Reference Citation Analysis]
157 Denesh D, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. Expert Rev Gastroenterol Hepatol 2021;15:1091-6. [PMID: 33653185 DOI: 10.1080/17474124.2021.1898944] [Reference Citation Analysis]
158 Simpson N, Seenan JP, Patel R, Kipgen D. Acute interstitial nephritis secondary to vedolizumab. BMJ Case Rep 2021;14:e243568. [PMID: 34799387 DOI: 10.1136/bcr-2021-243568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
160 Eskander A, Saadah OI, Abdelrazek AA, Mosli M, Alsufyani HA, Meshaal S, Hasnoon AM, Tarek S, Abdelgalil A. Prevalence of Celiac Disease in Children and Adolescents With Inflammatory Bowel Disease. Cureus 2020;12:e9977. [PMID: 32983679 DOI: 10.7759/cureus.9977] [Reference Citation Analysis]
161 Mountifield R. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary. J Gastroenterol Hepatol 2021;36 Suppl 1:25-6. [PMID: 33817852 DOI: 10.1111/jgh.15455] [Reference Citation Analysis]
162 Dowdell AS, Colgan SP. Metabolic Host-Microbiota Interactions in Autophagy and the Pathogenesis of Inflammatory Bowel Disease (IBD). Pharmaceuticals (Basel) 2021;14:708. [PMID: 34451805 DOI: 10.3390/ph14080708] [Reference Citation Analysis]
163 Dawson R, Wands DIF, Logan M, Bremner G, Efklides S, Benn L, Henderson P, Grant H, Meredith J, Armstrong K, Wilson DC, Gerasimidis K, Alex G, Russell RK. Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's Disease. Inflamm Bowel Dis 2022:izac039. [PMID: 35259266 DOI: 10.1093/ibd/izac039] [Reference Citation Analysis]
164 Kim H, Alten R, Cummings F, Danese S, D'Haens G, Emery P, Ghosh S, Gilletta de Saint Joseph C, Lee J, Lindsay JO, Nikiphorou E, Parker B, Schreiber S, Simoens S, Westhovens R, Jeong JH, Peyrin-Biroulet L. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs 2021;13:1868078. [PMID: 33557682 DOI: 10.1080/19420862.2020.1868078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Reference Citation Analysis]
166 Yu M, Ye Z, Chen Y, Qin T, Kou J, Tian D, Xiao F. Questionnaire assessment helps the self-management of patients with inflammatory bowel disease during the outbreak of Coronavirus Disease 2019. Aging (Albany NY) 2020;12:12468-78. [PMID: 32628131 DOI: 10.18632/aging.103525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
167 Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP. Drug Targeting of Inflammatory Bowel Diseases by Biomolecules. Nanomaterials (Basel) 2021;11:2035. [PMID: 34443866 DOI: 10.3390/nano11082035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
168 Moss JG, Parry CM, Holt RCL, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 2022;27:61. [PMID: 35488310 DOI: 10.1186/s40001-022-00687-y] [Reference Citation Analysis]
169 Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F, Cooney R, Dart RJ, Galloway J, Gaya DR, Ghosh S, Griffiths M, Hancock L, Hansen R, Hart A, Lamb CA, Lees CW, Limdi JK, Lindsay JO, Patel K, Powell N, Murray CD, Probert C, Raine T, Selinger C, Sebastian S, Smith PJ, Tozer P, Ustianowski A, Younge L, Samaan MA, Irving PM. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020;69:1769-1777. [PMID: 32513653 DOI: 10.1136/gutjnl-2020-321927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
170 Khosravi B, Salehnia A, Pak N, Montazeri SA, Sima AR, Vahedi H, Malekzadeh R, Radmard AR. A Practical Index to Distinguish Backwash Ileitis From Crohn's Terminal Ileitis in MR Enterography. Inflamm Bowel Dis 2022:izac040. [PMID: 35259254 DOI: 10.1093/ibd/izac040] [Reference Citation Analysis]
171 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
172 Rocha R, de J Santos G, Santana G. Influence of nutritional status in the postoperative period of patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2021; 12(5): 90-99 [PMID: 34616585 DOI: 10.4292/wjgpt.v12.i5.90] [Reference Citation Analysis]
173 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Premjeyanth V, Shipman AR, Shipman KE. Faecal calprotectin in dermatology practice. Clin Exp Dermatol 2020;45:831-5. [DOI: 10.1111/ced.14307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
175 Schreiner P, Mueller NJ, Fehr J, Maillard MH, Brand S, Michetti P, Schoepfer A, Restellini S, Vulliemoz M, Vavricka SR, Juillerat P, Rogler G, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. J Crohns Colitis. 2020;Online ahead of print. [PMID: 32592587 DOI: 10.1093/ecco-jcc/jjaa132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909. [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
177 Dhaliwal A, Williams FR, Quinlan JI, Allen SL, Greig C, Filer A, Raza K, Ghosh S, Lavery GG, Newsome PN, Choudhary S, Breen L, Armstrong MJ, Elsharkawy AM, Lord JM. Evaluation of the mechanisms of sarcopenia in chronic inflammatory disease: protocol for a prospective cohort study. Skelet Muscle 2021;11:27. [PMID: 34895316 DOI: 10.1186/s13395-021-00282-5] [Reference Citation Analysis]
178 Crespo J, Andrade R, Alberca de Las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-García J, Sánchez-Yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. Gastroenterol Hepatol 2020;43:332-47. [PMID: 32409107 DOI: 10.1016/j.gastrohep.2020.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 Terjung B, Schmelz R, Ehehalt R, Klaus J, Knop J, Schwind S, Wilke T, Stallmach A. Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review. Therap Adv Gastroenterol 2020;13:1756284820952592. [PMID: 33149762 DOI: 10.1177/1756284820952592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Reference Citation Analysis]
182 Zingone F, Buda A, Savarino E. Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre. Dig Liver Dis 2020;52:1248-9. [PMID: 32811778 DOI: 10.1016/j.dld.2020.07.021] [Reference Citation Analysis]
183 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Reference Citation Analysis]
184 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Kabir M, Fofaria R, Arebi N, Bassett P, Tozer PJ, Hart AL, Thomas-Gibson S, Humphries A, Suzuki N, Saunders B, Warusavitarne J, Faiz O, Wilson A. Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). Aliment Pharmacol Ther 2020;52:5-19. [PMID: 32432797 DOI: 10.1111/apt.15778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
186 Huang H, Liu B, Qu N, Zhang S, Bai X, Handley M, Shan F. Research progress of opioid growth factor in immune-related diseases and cancer diseases. Int Immunopharmacol 2021;99:107713. [PMID: 34426103 DOI: 10.1016/j.intimp.2021.107713] [Reference Citation Analysis]
187 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Li S, Li P, Sun H, Hu W, Hu S, Chen Y, Lv M. Medication Belief is Associated with Improved Adherence to Exclusive Enteral Nutrition in Patients with Crohn's Disease. Patient Prefer Adherence 2021;15:2327-34. [PMID: 34703215 DOI: 10.2147/PPA.S330842] [Reference Citation Analysis]
189 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 Chen QL, Yin HR, He QY, Wang Y. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother 2021;138:111442. [PMID: 33667791 DOI: 10.1016/j.biopha.2021.111442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
191 Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines 2021;9:101. [PMID: 33494227 DOI: 10.3390/biomedicines9020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
192 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Aliment Pharmacol Ther 2021. [PMID: 34796537 DOI: 10.1111/apt.16708] [Reference Citation Analysis]
193 Häuser W, Morlion B, Vowles KE, Bannister K, Buchser E, Casale R, Chenot JF, Chumbley G, Drewes AM, Dom G, Jutila L, O'Brien T, Pogatzki-Zahn E, Rakusa M, Suarez-Serrano C, Tölle T, Krčevski Škvarč N. European* clinical practice recommendations on opioids for chronic noncancer pain - Part 1: Role of opioids in the management of chronic noncancer pain. Eur J Pain 2021;25:949-68. [PMID: 33655607 DOI: 10.1002/ejp.1736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
194 Larussa T, Flauti D, Abenavoli L, Boccuto L, Suraci E, Marasco R, Imeneo M, Luzza F. The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study. J Clin Med 2020;9:E2416. [PMID: 32731482 DOI: 10.3390/jcm9082416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
195 Golusda L, Kühl AA, Siegmund B, Paclik D. Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response. Inflamm Bowel Dis 2021:izab290. [PMID: 34871378 DOI: 10.1093/ibd/izab290] [Reference Citation Analysis]
196 Meier JL. Viral Acute Gastroenteritis in Special Populations. Gastroenterol Clin North Am 2021;50:305-22. [PMID: 34024443 DOI: 10.1016/j.gtc.2021.02.003] [Reference Citation Analysis]
197 Wronka KM, Bik E, Milkiewicz P. Outcome of pregnancy in patients with primary sclerosing cholangitis. Dig Liver Dis 2021:S1590-8658(21)00731-3. [PMID: 34518127 DOI: 10.1016/j.dld.2021.08.015] [Reference Citation Analysis]
198 Wang Z, Chen J, Chen Z, Xie L, Wang W. Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora. Saudi J Gastroenterol 2021;27:149-57. [PMID: 33835051 DOI: 10.4103/sjg.SJG_462_20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Núñez P, Quera R, Flores L, Araya R, Córdova A, Correa I. Role of the multidisciplinary team in pandemics: A new opportunity to achieve greater immunization in patients with inflammatory bowel disease. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2021.12.013] [Reference Citation Analysis]
201 El-Nakeep S, Shawky A, Abbas SF, Abdel Latif O. Stem cell transplantation for induction of remission in medically refractory Crohn's disease. Cochrane Database Syst Rev 2022;5:CD013070. [PMID: 35556242 DOI: 10.1002/14651858.CD013070.pub2] [Reference Citation Analysis]
202 Zanelli J, Chandrapalan S, Patel A, Arasaradnam RP. The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937089. [PMID: 33281933 DOI: 10.1177/1756284820937089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Rosano G, Schiefke I, Göhring UM, Fabien V, Bonassi S, Stein J. A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. J Clin Med 2020;9:E3587. [PMID: 33172157 DOI: 10.3390/jcm9113587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
204 Hansen R, Meade S, Beattie RM, Auth MK, Croft N, Davies P, Devadason D, Doherty C, Epstein J, Howarth L, Kiparissi F, Muhammed R, Shivamurthy V, Spray C, Stanton MP, Torrente F, Urs A, Wilson D, Irving PM, Samaan M, Kammermeier J. Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut 2021;70:1044-52. [PMID: 32873696 DOI: 10.1136/gutjnl-2020-322449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
205 MacFarlane H, Baldock TE, McLean RC, Brown LR. Patient Outcomes Following Emergency Bowel Resection for Inflammatory Bowel Disease and the Impact of Surgical Subspecialisation in the North of England: A Retrospective Cohort Study. World J Surg 2021;45:1376-89. [PMID: 33506292 DOI: 10.1007/s00268-020-05947-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Jones NP. Comment on: Systemic corticosteroid use in UK Uveitis practice: results from the ocular inflammation steroid toxicity risk (OSTRICH) study. Eye (Lond) 2022. [PMID: 35322212 DOI: 10.1038/s41433-022-02031-4] [Reference Citation Analysis]
207 Radford SJ, Clarke C, Shinkins B, Leighton P, Taylor S, Moran G. Clinical utility of small bowel ultrasound assessment of Crohn’s disease in adults: a systematic scoping review. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101897] [Reference Citation Analysis]
208 Bower JAJ, O'Flynn L, Kakad R, Aldulaimi D. Effect of inflammatory bowel disease treatments on patients with diabetes mellitus. World J Diabetes 2021; 12(8): 1248-1254 [PMID: 34512890 DOI: 10.4239/wjd.v12.i8.1248] [Reference Citation Analysis]
209 Yan ZX, Liu YM, Ma T, Xu MJ, Zhang XB, Zha XJ, Yang JH, Jiang P, Chen X, Lin ZW, Wu YH, Zu RZ, Lin WR, Lin XY. Efficacy and safety of retention enema with traditional Chinese medicine for ulcerative colitis: A meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2021;42:101278. [PMID: 33276227 DOI: 10.1016/j.ctcp.2020.101278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Takeyama E, Wada H, Sato S, Tomooka K, Ikeda A, Tanigawa T. Association of diagnostic delay with medical cost for patients with Crohn's disease: A Japanese claims-based cohort study. JGH Open 2021;5:568-72. [PMID: 34013056 DOI: 10.1002/jgh3.12534] [Reference Citation Analysis]
211 Altemus J, Dadgar N, Li Y, Lightner AL. Adipose tissue-derived mesenchymal stem cells' acellular product extracellular vesicles as a potential therapy for Crohn's disease. J Cell Physiol 2022. [PMID: 35522572 DOI: 10.1002/jcp.30756] [Reference Citation Analysis]
212 Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Reference Citation Analysis]
213 Anikhindi SA, Kumar A, Arora A. COVID-19 in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2020;14:1187-93. [PMID: 32856955 DOI: 10.1080/17474124.2020.1816822] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
214 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Reference Citation Analysis]
215 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
216 Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World J Gastrointest Oncol 2022; 14(3): 547-567 [DOI: 10.4251/wjgo.v14.i3.547] [Reference Citation Analysis]
217 Guan Y, Hao Y, Guan Y, Bu H, Wang H. Effects of vitamin D supplementation on blood markers in ulcerative colitis patients: a systematic review and meta-analysis. Eur J Nutr 2021. [PMID: 34075433 DOI: 10.1007/s00394-021-02603-2] [Reference Citation Analysis]
218 Vrdoljak J, Kumric M, Ticinovic Kurir T, Males I, Martinovic D, Vilovic M, Bozic J. Effects of Wine Components in Inflammatory Bowel Diseases. Molecules 2021;26:5891. [PMID: 34641434 DOI: 10.3390/molecules26195891] [Reference Citation Analysis]
219 Zhao Z, Yuan X, Cui Y, Liu J, Shen J, Jin B, Feng B, Zhai Y, Zheng M, Kou G, Zhou R, Li L, Zuo X, Li S, Li Y. Melatonin Mitigates Oxazolone-Induced Colitis in Microbiota-Dependent Manner. Front Immunol 2022;12:783806. [DOI: 10.3389/fimmu.2021.783806] [Reference Citation Analysis]
220 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Boldovjakova D, Scrimgeour DSG, Parnaby CN, Ramsay G. Improved outcomes for patients undergoing colectomy for acute severe inflammatory colitis by adopting a multi-disciplinary care bundle. J Gastrointest Surg 2021. [PMID: 34282524 DOI: 10.1007/s11605-021-05082-2] [Reference Citation Analysis]
222 Ye TY, Mei Y, Bao DN, Zhu YF, Xu XH, Zhu LF. Maternal anti-tumour necrosis factor-α drug use during pregnancy and risk of infection in the offspring: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1112-7. [PMID: 33376073 DOI: 10.1016/j.dld.2020.11.033] [Reference Citation Analysis]
223 Mokros Ł, Domżał-Magrowska D, Pietras T, Sipowicz K, Talar-Wojnarowska R. The Association between Temperament, Chronotype, Depressive Symptoms, and Disease Activity among Patients with Inflammatory Bowel Disease-A Cross-Sectional Pilot Study. Life (Basel) 2021;11:1347. [PMID: 34947878 DOI: 10.3390/life11121347] [Reference Citation Analysis]
224 Sicilia B, Vicente R, Arias L, Echarri A, Zabana Y, Mañosa M, Beltrán B, Barreiro-de Acosta M; en nombre de GETECCU. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. Gastroenterol Hepatol 2021;44:435-47. [PMID: 33592179 DOI: 10.1016/j.gastrohep.2020.12.011] [Reference Citation Analysis]
225 Łodyga M, Eder P, Dobrowolska A, Reguła J, Rydzewska G. The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. Prz Gastroenterol 2020;15:85-8. [PMID: 32550938 DOI: 10.5114/pg.2020.94544] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Comeche JM, Gutierrez-Hervás A, Tuells J, Altavilla C, Caballero P. Predefined Diets in Patients with Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Nutrients 2020;13:E52. [PMID: 33375314 DOI: 10.3390/nu13010052] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
227 Niriella MA, Liyanage IK, Kodisinghe SK, De Silva AP, Jayatissa AVGAM, Navarathne NMM, Peiris RK, Kalubovila UP, Kumarasena SR, Jayasekara RW, de Silva HJ. Changing phenotype, early clinical course and clinical predictors of inflammatory bowel disease in Sri Lanka: a retrospective, tertiary care-based, multi-centre study. BMC Gastroenterol 2021;21:71. [PMID: 33593289 DOI: 10.1186/s12876-021-01644-5] [Reference Citation Analysis]
228 Fiske J, Conley T, Sebastian S, Subramanian S. Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterol 2020;11:427-9. [PMID: 33104078 DOI: 10.1136/flgastro-2020-101407] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
229 Guzman-Prado Y, Samson O, Segal JP, Limdi JK, Hayee B. Vitamin D Therapy in Adults With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2020;26:1819-30. [PMID: 32385487 DOI: 10.1093/ibd/izaa087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
230 Khan F, Person H, Dekio F, Ogawa M, Ho HE, Dunkin D, Secord E, Cunningham-Rundles C, Ward SC. Crohn's-like Enteritis in X-Linked Agammaglobulinemia: A Case Series and Systematic Review. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00579-1. [PMID: 34029777 DOI: 10.1016/j.jaip.2021.04.070] [Reference Citation Analysis]
231 Tokuyama M, Dhingra S, Polydorides AD. Clinicopathologic Features and Diagnostic Implications of Pyloric Gland Metaplasia in Intestinal Specimens. Am J Surg Pathol 2021;45:365-73. [PMID: 33105158 DOI: 10.1097/PAS.0000000000001608] [Reference Citation Analysis]
232 Jones K, Baker K, Speight RA, Thompson NP, Tew GA. Randomised clinical trial: Combined impact and resistance training in adults with stable Crohn’s disease. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
233 Kim M, Jeon J. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. IJMS 2022;23:2846. [DOI: 10.3390/ijms23052846] [Reference Citation Analysis]
234 Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory Bowel Diseases: Is There a Role for Nutritional Suggestions? Nutrients 2021;13:1387. [PMID: 33924119 DOI: 10.3390/nu13041387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2021. [PMID: 34751954 DOI: 10.1111/apt.16656] [Reference Citation Analysis]
236 Xiang BJ, Huang YH, Dai C. A Rare Autoinflammatory Syndrome Involving Acute Severe Ulcerative Colitis Combined With Iritis. Inflamm Bowel Dis 2021;27:e83-6. [PMID: 33694367 DOI: 10.1093/ibd/izab043] [Reference Citation Analysis]
237 Avery P. Developments and challenges of e-health strategies for people with inflammatory bowel disease. British Journal of Healthcare Management 2020;26:73-6. [DOI: 10.12968/bjhc.2020.0010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
238 D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020;51:689-698. [PMID: 32048751 DOI: 10.1111/apt.15662] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
239 Albishi AM, Chakik R, Bazeed M. Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy. Case Rep Gastrointest Med 2021;2021:5593067. [PMID: 33968453 DOI: 10.1155/2021/5593067] [Reference Citation Analysis]
240 Liu X, Li Y, Wu K, Shi Y, Chen M. Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2021;2021:6612970. [PMID: 33981340 DOI: 10.1155/2021/6612970] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Clark-Snustad K, Butnariu M, Afzali A. Women's Health and Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:769-89. [PMID: 33121695 DOI: 10.1016/j.gtc.2020.07.004] [Reference Citation Analysis]
242 Wellens J, Vermeire S, Sabino J. Let Food Be Thy Medicine-Its Role in Crohn's Disease. Nutrients 2021;13:832. [PMID: 33802429 DOI: 10.3390/nu13030832] [Reference Citation Analysis]
243 Na SY, Lim YJ. Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom? Diagnostics (Basel) 2021;11:2240. [PMID: 34943477 DOI: 10.3390/diagnostics11122240] [Reference Citation Analysis]
244 Gerasimidis K, Godny L, Sigall-boneh R, Svolos V, Wall C, Halmos E. Current recommendations on the role of diet in the aetiology and management of IBD. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2020-101429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Li X, Liu S, Liu H, Zhu JJ. Acupuncture for gastrointestinal diseases. Anat Rec (Hoboken) 2022. [PMID: 35148031 DOI: 10.1002/ar.24871] [Reference Citation Analysis]
246 Hart A, D'Haens G, Bereswill M, Finney-Hayward T, Kalabic J, Levy G, Liang H, Seow CH, Loftus EV Jr, Panaccione R, Reinisch W, Satsangi J. Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. United European Gastroenterol J 2022. [PMID: 35560533 DOI: 10.1002/ueg2.12236] [Reference Citation Analysis]
247 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
248 Aardoom MA, Klomberg RCW, Kemos P, Ruemmele FM, van Ommen H, de Ridder L, Croft NM. The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease; a prospective international cohort study based on the PIBD-SETQuality Safety Registry. J Crohns Colitis 2021:jjab171. [PMID: 34599822 DOI: 10.1093/ecco-jcc/jjab171] [Reference Citation Analysis]
249 Ziv Y, Swaminath A, Sultan K. Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical. Inflamm Bowel Dis 2022:izac072. [PMID: 35416978 DOI: 10.1093/ibd/izac072] [Reference Citation Analysis]
250 Gioxari A, Amerikanou C, Papada E, Zioga E, Georgoulis AD, Bamias G, Kaliora AC. Serum Vitamins D, B9 and B12 in Greek Patients with Inflammatory Bowel Diseases. Nutrients 2020;12:E3734. [PMID: 33291539 DOI: 10.3390/nu12123734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
251 Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. [PMID: 34233964 DOI: 10.1136/jitc-2021-002742] [Reference Citation Analysis]
252 Su L, Su Y, An Z, Zhang P, Yue Q, Zhao C, Sun X, Zhang S, Liu X, Li K, Zhao L. Fermentation products of Danshen relieved dextran sulfate sodium-induced experimental ulcerative colitis in mice. Sci Rep 2021;11:16210. [PMID: 34376708 DOI: 10.1038/s41598-021-94594-7] [Reference Citation Analysis]
253 Giri S, Sundaram S. Low Dose Azathioprine with Allopurinol in IBD: Early Days to Call It a Recipe for Success. Dig Dis Sci 2022. [PMID: 35244826 DOI: 10.1007/s10620-021-07375-7] [Reference Citation Analysis]
254 Prasad SS, Keely S, Talley NJ, Kairuz T, Walker MM. Pharmacists' Confidence in Managing Patients with Inflammatory Bowel Disease. Pharmacy (Basel) 2020;8:E68. [PMID: 32316504 DOI: 10.3390/pharmacy8020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
255 Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
256 Ahmedy OA, Ibrahim SM, Salem HH, Kandil EA. Antiulcerogenic effect of melittin via mitigating TLR4/TRAF6 mediated NF-κB and p38MAPK pathways in acetic acid-induced ulcerative colitis in mice. Chem Biol Interact 2020;331:109276. [PMID: 33002459 DOI: 10.1016/j.cbi.2020.109276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
257 Wang S, Zhou P, Li Z. A Case Report and Literature Review of Mesalazine-Induced Kidney Injury in a Pediatric Patient With Ulcerative Colitis. Front Pediatr 2022;10:808472. [DOI: 10.3389/fped.2022.808472] [Reference Citation Analysis]
258 Grammatikopoulou MG, Goulis DG, Gkiouras K, Nigdelis MP, Papageorgiou ST, Papamitsou T, Forbes A, Bogdanos DP. Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials. Nutrients 2020;12:E3648. [PMID: 33260902 DOI: 10.3390/nu12123648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
259 Popa IV, Burlacu A, Mihai C, Prelipcean CC. A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents. Medicina (Kaunas) 2020;56:E628. [PMID: 33233514 DOI: 10.3390/medicina56110628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
260 Albayrak NE, Polydorides AD. Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation. Am J Surg Pathol 2022. [PMID: 35354161 DOI: 10.1097/PAS.0000000000001883] [Reference Citation Analysis]
261 Harris RE, Duncan H, Buchanan E, Cardigan T, Garrick V, Curtis L, Gervais L, Barclay A, Haddock G, Hansen R, Tayler R, Walker G, Russell RK. Prehabilitation: The Impact of Preoperative Exclusive Enteral Nutrition on Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2020;70:503-7. [PMID: 31880668 DOI: 10.1097/MPG.0000000000002595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
262 Gu Z, Zhu Y, Mei F, Dong X, Xia G, Shen X. Tilapia head glycolipids protect mice against dextran sulfate sodium-induced colitis by ameliorating the gut barrier and suppressing NF-kappa B signaling pathway. Int Immunopharmacol 2021;96:107802. [PMID: 34162163 DOI: 10.1016/j.intimp.2021.107802] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Oudman E, Wijnia JW, Oey MJ, van Dam M, Postma A. Wernicke's encephalopathy in Crohn's disease and ulcerative colitis. Nutrition 2021;86:111182. [PMID: 33611107 DOI: 10.1016/j.nut.2021.111182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Younge L, Mason I, Kapasi R. Specialist inflammatory bowel disease nursing in the UK: current situation and future proofing. Frontline Gastroenterol 2021;12:169-74. [PMID: 33907615 DOI: 10.1136/flgastro-2019-101354] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
266 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
267 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Segal JP, Smith PJ. Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis. Aliment Pharmacol Ther 2020;52:733-4. [PMID: 33545748 DOI: 10.1111/apt.15949] [Reference Citation Analysis]
269 Almuntashri F, Binyaseen K, Alkhotani A. Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn's Disease on Infliximab Therapy. Cureus 2021;13:e19041. [PMID: 34858738 DOI: 10.7759/cureus.19041] [Reference Citation Analysis]
270 Palchaudhuri S, Albenberg L, Lewis JD. Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. Crohns Colitis 360 2020;2:otaa059. [PMID: 33954288 DOI: 10.1093/crocol/otaa059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Fernández-Sánchez M, Ribes-Artero H, Romá-Sánchez E, Gómez-Portero MR, Guerrero-Hurtado E, García-Pellicer J, Poveda-Andrés JL. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res 2021. [PMID: 34309233 DOI: 10.1002/bdr2.1942] [Reference Citation Analysis]
272 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
273 Williams I, Pandey S, Haller W, Huynh HQ, Chan A, Düeker G, Bettels R, Peyrin-biroulet L, Dike CR, Degeeter C, Smith D, Al Eisa N, Platt N, Marquardt T, Schwerd T, Platt FM, Uhlig HH. Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C. Wellcome Open Res 2022;7:11. [DOI: 10.12688/wellcomeopenres.16986.1] [Reference Citation Analysis]
274 Kennedy NA, Jones G, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984-90. [DOI: 10.1136/gutjnl-2020-321244] [Reference Citation Analysis]
275 Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2021;14:17562848211013249. [PMID: 34046083 DOI: 10.1177/17562848211013249] [Reference Citation Analysis]
276 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
277 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Wan Q, Zhao R, Xia L, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu XT. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies. J Cancer Res Clin Oncol 2021;147:1077-87. [PMID: 33433655 DOI: 10.1007/s00432-020-03496-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
279 Raine T, Gkini MA, Irving PM, Kaul A, Korendowych E, Laws P, Foulkes AC. Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists. BioDrugs 2021;35:187-99. [PMID: 33635522 DOI: 10.1007/s40259-020-00464-5] [Reference Citation Analysis]
280 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
281 López-Serrano A, Suárez MJ, Besó P, Algarra A, Latorre P, Barrachina MM, Paredes JM. Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study. Scand J Gastroenterol 2021;56:820-8. [PMID: 34043920 DOI: 10.1080/00365521.2021.1925339] [Reference Citation Analysis]
282 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
283 Pagnini C, Di Paolo MC, Graziani MG, Delle Fave G. Probiotics and Vitamin D/Vitamin D Receptor Pathway Interaction: Potential Therapeutic Implications in Inflammatory Bowel Disease. Front Pharmacol 2021;12:747856. [PMID: 34899302 DOI: 10.3389/fphar.2021.747856] [Reference Citation Analysis]
284 Waked B, Holvoet T, Geldof J, Baert F, Pattyn P, Lobatón T, Hindryckx P. Conservative management of spontaneous intra-abdominal abscess in Crohn's disease: Outcome and prognostic factors. J Dig Dis 2021;22:263-70. [PMID: 33742782 DOI: 10.1111/1751-2980.12984] [Reference Citation Analysis]
285 Sienkiewicz M, Szymańska P, Maciejewska O, Niewiadomska J, Wiśniewska‐jarosińska M, Fichna J. Assessment of dietary habits in inflammatory bowel disease patients: A cross‐sectional study from Poland. Nutr Bull 2021;46:432-42. [DOI: 10.1111/nbu.12525] [Reference Citation Analysis]
286 Deputy M, Sahnan K, Worley G, Patel K, Balinskaite V, Bottle A, Aylin P, Burns EM, Hart A, Faiz O. The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study. Aliment Pharmacol Ther 2022. [PMID: 35132663 DOI: 10.1111/apt.16800] [Reference Citation Analysis]
287 Kim JM, Kang JG, Kim S, Cheon JH. Deep-learning system for real-time differentiation between Crohn's disease, intestinal Behçet's disease, and intestinal tuberculosis. J Gastroenterol Hepatol 2021;36:2141-8. [PMID: 33554375 DOI: 10.1111/jgh.15433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Matsuda K, Hashiguchi Y, Asako K, Okada Y, Ohno K, Tsukamoto M, Fukushima Y, Shimada R, Ozawa T, Hayama T, Nozawa K, Fukagawa T, Kikuchi Y, Sasajima Y. A young woman who developed ascending colon cancer 2 years after the onset of ulcerative colitis. Clin J Gastroenterol 2020;13:1189-95. [PMID: 32780275 DOI: 10.1007/s12328-020-01207-3] [Reference Citation Analysis]
289 Chiba M, Morita N, Nakamura A, Tsuji K, Harashima E. Increased Incidence of Inflammatory Bowel Disease in Association with Dietary Transition (Westernization) in Japan. JMA J 2021;4:347-57. [PMID: 34796289 DOI: 10.31662/jmaj.2021-0038] [Reference Citation Analysis]
290 Quera R, Simian D, Núñez P, Flores L. Immunization in patients with inflammatory bowel disease: Still far from standards. Dig Liver Dis 2021;53:1519-20. [PMID: 34148863 DOI: 10.1016/j.dld.2021.05.030] [Reference Citation Analysis]
291 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
292 Scott R, Parker H, Mccartney S, Harrow P, Williams D, Giles I. Outcomes following biosimilar TNF inhibitors use for inflammatory-mediated immune disorders in pregnancy. Obstet Med. [DOI: 10.1177/1753495x211028779] [Reference Citation Analysis]
293 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
294 Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
295 Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of Mesenchymal Stem Cell-Derived Exosomes on Autoimmune Diseases. Front Immunol 2021;12:749192. [PMID: 34646275 DOI: 10.3389/fimmu.2021.749192] [Reference Citation Analysis]
296 Liu S, Zhao W, Lan P, Mou X. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell 2021;12:331-45. [PMID: 32601832 DOI: 10.1007/s13238-020-00745-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
297 Le Fevre ER, McGrath KH, Fitzgerald DA. Pulmonary Manifestations of Gastrointestinal, Pancreatic, and Liver Diseases in Children. Pediatr Clin North Am 2021;68:41-60. [PMID: 33228942 DOI: 10.1016/j.pcl.2020.09.002] [Reference Citation Analysis]
298 Zhou YF, Sun N, Cheng SR, Deng XD, Ye XY, Li ZJ, Zhou J, Xu GX, Qu YZ, Huang LY, Sun RR, Liang FR. Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis. BMJ Open 2021;11:e045090. [PMID: 34429304 DOI: 10.1136/bmjopen-2020-045090] [Reference Citation Analysis]
299 Hsieh PC, Cheng CF, Wu CW, Tzeng IS, Kuo CY, Hsu PS, Lee CT, Yu MC, Lan CC. Combination of Acupoints in Treating Patients with Chronic Obstructive Pulmonary Disease: An Apriori Algorithm-Based Association Rule Analysis. Evid Based Complement Alternat Med 2020;2020:8165296. [PMID: 32595739 DOI: 10.1155/2020/8165296] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
300 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Reference Citation Analysis]
301 Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ 2020;192:E295-301. [PMID: 32392512 DOI: 10.1503/cmaj.191012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
302 Bqain M, Efimov A, Baker D, Kang AS. Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review. Hum Antibodies 2021. [PMID: 34151784 DOI: 10.3233/HAB-210449] [Reference Citation Analysis]
303 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Reference Citation Analysis]
304 Finucci A, Ditto MC, Parisi S, Borrelli R, Priora M, Realmuto C, Fusaro E. Rheumatic manifestations in inflammatory bowel disease. Minerva Gastroenterol (Torino) 2021;67:79-90. [PMID: 32623869 DOI: 10.23736/S2724-5985.20.02726-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Gordon-Dixon A, Hampal R, Miah A, Webb-Butler S, Lewis W, Ross R, Ghosh N, Grimes C. Does exclusive enteral nutrition reduce the rate of stoma formation in patients requiring ileocolic resection for Crohn's disease? A single center experience. Clin Nutr ESPEN 2021;44:282-6. [PMID: 34330480 DOI: 10.1016/j.clnesp.2021.05.030] [Reference Citation Analysis]
306 Gong M, Zhang F, Miao Y, Niu J. Advances of Heat Shock Family in Ulcerative Colitis. Front Pharmacol 2022;13:869930. [DOI: 10.3389/fphar.2022.869930] [Reference Citation Analysis]
307 Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis. 2020;14:1162-1171. [PMID: 32103246 DOI: 10.1093/ecco-jcc/jjaa036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
308 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
309 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598-606. [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
311 Alhalabi MM, Abbas AJ. Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 2022;75:103456. [DOI: 10.1016/j.amsu.2022.103456] [Reference Citation Analysis]
312 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
313 Carriss-Wright J. Running a one-stop clinic for patients with inflammatory bowel disease. Br J Nurs 2021;30:190-1. [PMID: 33565929 DOI: 10.12968/bjon.2021.30.3.190] [Reference Citation Analysis]
314 Yue B, Yu ZL, Lv C, Geng XL, Wang ZT, Dou W. Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease. World J Gastroenterol 2020; 26(30): 4378-4393 [PMID: 32874052 DOI: 10.3748/wjg.v26.i30.4378] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Texler B, Zollner A, Reinstadler V, Reider SJ, Macheiner S, Jelusic B, Pfister A, Watschinger C, Przysiecki N, Tilg H, Oberacher H, Moschen AR. Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00192-2. [PMID: 34624526 DOI: 10.1016/j.jcmgh.2021.09.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
317 Nevejan L, Strypens T, Van Nieuwenhove M, Boel A, Cattoir L, Meeus P, Bossuyt X, De Neve N, Van Hoovels L. Prognostic value of circulating calprotectin levels on the clinical course of COVID-19 differs between serum, heparin, EDTA and citrate sample types. Clin Chim Acta 2021;525:54-61. [PMID: 34919937 DOI: 10.1016/j.cca.2021.12.011] [Reference Citation Analysis]
318 Priadko K, Moretti A, Iolascon G, Gravina AG, Miranda A, Sgambato D, De Musis C, Romano M, Gimigliano F. Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin. JCM 2022;11:1840. [DOI: 10.3390/jcm11071840] [Reference Citation Analysis]
319 Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: Are we there yet? J Gastroenterol Hepatol 2021;36 Suppl 1:8-9. [PMID: 33817841 DOI: 10.1111/jgh.15447] [Reference Citation Analysis]
320 Arkteg CB, Goll R, Gundersen MD, Anderssen E, Fenton C, Florholmen J. Mucosal gene transcription of ulcerative colitis in endoscopic remission. Scand J Gastroenterol 2020;55:139-47. [PMID: 31918598 DOI: 10.1080/00365521.2019.1710245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
321 Pepe M, Carulli E, Forleo C, Moscarelli M, Di Cillo O, Bortone AS, Nestola PL, Biondi-Zoccai G, Giordano A, Favale S. Inflammatory Bowel Disease and Acute Coronary Syndromes: From Pathogenesis to the Fine Line Between Bleeding and Ischemic Risk. Inflamm Bowel Dis 2021;27:725-31. [PMID: 32592478 DOI: 10.1093/ibd/izaa160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
322 Zingone F, Buda A, Savarino EV. Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Dig Liver Dis 2020;52:604-5. [PMID: 32360133 DOI: 10.1016/j.dld.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
323 Armuzzi A, Bortoli A, Castiglione F, Contaldo A, Daperno M, D'Incà R, Labarile N, Mazzuoli S, Onali S, Milla M, Orlando A, Principi M, Pugliese D, Renna S, Rizzello F, Scribano ML, Todeschini A; Italian Group for the Study of Inflammatory Bowel Disease Working Group. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis 2021:S1590-8658(21)00271-1. [PMID: 34120858 DOI: 10.1016/j.dld.2021.05.020] [Reference Citation Analysis]
324 Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. J Crohns Colitis 2021;15:462-70. [PMID: 32931556 DOI: 10.1093/ecco-jcc/jjaa189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Reference Citation Analysis]
326 Ramírez-Sánchez AD, Tan IL, Gonera-de Jong BC, Visschedijk MC, Jonkers I, Withoff S. Molecular Biomarkers for Celiac Disease: Past, Present and Future. Int J Mol Sci 2020;21:E8528. [PMID: 33198309 DOI: 10.3390/ijms21228528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Mullish BH, Quraishi MN, Segal JP, Ianiro G, Iqbal TH. The gut microbiome: what every gastroenterologist needs to know. Frontline Gastroenterol 2021;12:118-27. [PMID: 33613943 DOI: 10.1136/flgastro-2019-101376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
328 Zielińska AK, Sałaga M, Siwiński P, Włodarczyk M, Dziki A, Fichna J. Oxidative Stress Does Not Influence Subjective Pain Sensation in Inflammatory Bowel Disease Patients. Antioxidants (Basel) 2021;10:1237. [PMID: 34439485 DOI: 10.3390/antiox10081237] [Reference Citation Analysis]
329 Moradi S, Zobeiri M, Feizi A, Clark CCT, Entezari MH. The effects of spirulina (Arthrospira platensis) supplementation on anthropometric indices, blood pressure, sleep quality, mental health, fatigue status and quality of life in patients with ulcerative colitis: A randomised, double-blinded, placebo-controlled trial. Int J Clin Pract 2021;:e14472. [PMID: 34107141 DOI: 10.1111/ijcp.14472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
331 Watanabe S, Nishimura R, Shirasaki T, Katsukura N, Hibiya S, Kirimura S, Negi M, Okamoto R, Matsumoto Y, Nakamura T, Watanabe M, Tsuchiya K. Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis. J Crohns Colitis 2021:jjab032. [PMID: 33596306 DOI: 10.1093/ecco-jcc/jjab032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
332 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
333 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
334 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
335 Richards T, Breymann C, Brookes MJ, Lindgren S, Macdougall IC, McMahon LP, Munro MG, Nemeth E, Rosano GMC, Schiefke I, Weiss G. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. Ann Med 2021;53:274-85. [PMID: 33426933 DOI: 10.1080/07853890.2020.1867323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
336 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A. Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World J Gastroenterol 2021; 27(47): 8047-8057 [DOI: 10.3748/wjg.v27.i47.8047] [Reference Citation Analysis]
337 Haider SA, Yadav A, Perry C, Su L, Akanbi O, Kudaravalli P, Tripathi N, Hashim MA, Abdelsalam M, Hussein M, Elkheshen A, Patel V, Ali SE, Lamb L, Ingram K, Mayne C, Stuffelbeam AB, Flomenhoft D, Stromberg A, Barrett TA. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820959245. [PMID: 33133239 DOI: 10.1177/1756284820959245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
338 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Reference Citation Analysis]
339 Chien TH, Puig A, Khuong T, Kouhkamari MH, Che S, Huang TH. An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease. Biologics 2021;15:237-45. [PMID: 34163137 DOI: 10.2147/BTT.S310076] [Reference Citation Analysis]
340 Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00642-X. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Reference Citation Analysis]
341 Quraishi MN, Iqbal TH, Hart AL. Precision Medicine with FMT for Ulcerative Colitis: Are We There Yet? J Crohns Colitis 2021;15:519-20. [PMID: 33079179 DOI: 10.1093/ecco-jcc/jjaa190] [Reference Citation Analysis]
342 Papa A, Scaldaferri F, Vetrone LM, Neri M, Gasbarrini A, Lopetuso LR. How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines (Basel) 2021;9:248. [PMID: 33808983 DOI: 10.3390/vaccines9030248] [Reference Citation Analysis]
343 Ala M, Kheyri Z. The rationale for selenium supplementation in inflammatory bowel disease: A mechanism-based point of view. Nutrition 2021;85:111153. [PMID: 33578241 DOI: 10.1016/j.nut.2021.111153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
344 Shariff S, Moran G, Grimes C, Cooney RM. Current Use of EEN in Pre-Operative Optimisation in Crohn's Disease. Nutrients 2021;13:4389. [PMID: 34959941 DOI: 10.3390/nu13124389] [Reference Citation Analysis]
345 Rodríguez-Lago I, Mesonero F, Hijos-Mallada G, Cañas M, Saldaña R, Savini C, Fernández S, Juliá B, Cea-Calvo L; ACCU, GETECCU, GETEII. Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey. Gastroenterol Hepatol 2021:S0210-5705(21)00227-2. [PMID: 34400189 DOI: 10.1016/j.gastrohep.2021.07.009] [Reference Citation Analysis]
346 Toçoglu A, Dheir H, Demirci T, Kurt R, Salihi S, Yaylaci S, Çakar GÇ, Toptan H, Karabay O, Sipahi S. The effectiveness of dexamethasone on the prognosis of dialysis patients with severe COVID-19. Rev Assoc Med Bras (1992) 2021;67:1299-304. [PMID: 34816924 DOI: 10.1590/1806-9282.20210600] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Shaffer SR, Erondu AI, Traboulsi C, Rai V, Krugliak Cleveland N, Israel A, Christensen B, Rubin DT. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis 2021:izab130. [PMID: 34037230 DOI: 10.1093/ibd/izab130] [Reference Citation Analysis]
348 Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 2021;:1-16. [PMID: 33567923 DOI: 10.1080/14712598.2021.1889511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Dhaliwal A, Quinlan JI, Overthrow K, Greig C, Lord JM, Armstrong MJ, Cooper SC. Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview. Nutrients 2021;13:656. [PMID: 33671473 DOI: 10.3390/nu13020656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
350 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Reference Citation Analysis]
351 Arslan F, Vahaboğlu H. Cytomegalovirus and inflammatory bowel disease; reconsidering a 'result or reason dilemma' in terms of viral pathogenesis and medical ethics. Expert Rev Gastroenterol Hepatol 2020;14:307-9. [PMID: 32228242 DOI: 10.1080/17474124.2020.1745631] [Reference Citation Analysis]
352 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Authors' reply. Aliment Pharmacol Ther 2022;55:366-7. [PMID: 35040167 DOI: 10.1111/apt.16759] [Reference Citation Analysis]
353 Losurdo G, Brescia IV, Lillo C, Mezzapesa M, Barone M, Principi M, Ierardi E, Di Leo A, Rendina M. Liver involvement in inflammatory bowel disease: What should the clinician know? World J Hepatol 2021; 13(11): 1534-1551 [PMID: 34904028 DOI: 10.4254/wjh.v13.i11.1534] [Reference Citation Analysis]
354 Blackwell J, Alexakis C, Saxena S, Creese H, Bottle A, Petersen I, Hotopf M, Pollok RCG. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study. BMJ Open Gastroenterol 2021;8:e000588. [PMID: 34045238 DOI: 10.1136/bmjgast-2020-000588] [Reference Citation Analysis]
355 Jones JL, Benchimol EI, Bernstein CN, Huang JG, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Kaplan GG, Kuenzig ME, Tandon P, Targownik LE, Windsor JW, Bitton A. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. J Can Assoc Gastroenterol 2021;4:S61-7. [PMID: 34755041 DOI: 10.1093/jcag/gwab034] [Reference Citation Analysis]
356 Hart A. Commentary: safety of anti-TNF use in pregnancy. Aliment Pharmacol Ther 2020;51:205-6. [PMID: 31850565 DOI: 10.1111/apt.15548] [Reference Citation Analysis]
357 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Reference Citation Analysis]
358 Gilca-Blanariu GE, Trifan A, Ciocoiu M, Popa IV, Burlacu A, Balan GG, Olteanu AV, Stefanescu G. Magnesium-A Potential Key Player in Inflammatory Bowel Diseases? Nutrients 2022;14:1914. [PMID: 35565881 DOI: 10.3390/nu14091914] [Reference Citation Analysis]
359 Okobi OE, Udoete IO, Fasehun OO, Okobi T, Evbayekha EO, Ekabua JJ, Elukeme H, Ebong IL, Ajayi OO, Olateju IV, Taiwo A, Anaya IC, Omole JA, Nkongho MB, Ojinnaka U, Ajibowo AO, Ogbeifun OE, Ugbo OO, Okorare O, Akinsola Z, Olusoji RA, Amanze IO, Nwafor JN, Ukoha NA, Elimihele TA. A Review of Four Practice Guidelines of Inflammatory Bowel Disease. Cureus 2021;13:e16859. [PMID: 34513436 DOI: 10.7759/cureus.16859] [Reference Citation Analysis]
360 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Reference Citation Analysis]
361 Nguyen ALH, Sparrow MP. Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Dig Dis Sci 2021;66:3250-62. [PMID: 33073334 DOI: 10.1007/s10620-020-06662-z] [Reference Citation Analysis]
362 Liso M, Sila A, Verna G, Scarano A, Donghia R, Castellana F, Cavalcanti E, Pesole PL, Sommella EM, Lippolis A, Armentano R, Giudetti AM, Vergara D, Campiglia P, Sardone R, Curlo M, Mastronardi M, Petroni K, Tonelli C, Santino A, Chieppa M. Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study. Antioxidants 2022;11:138. [DOI: 10.3390/antiox11010138] [Reference Citation Analysis]
363 Silva JC, Fernandes C, Rodrigues J, Fernandes S, Ponte A, Rodrigues A, Silva AP, Gomes AC, Afecto E, Correia J, Carvalho J. Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. Scand J Gastroenterol 2020;55:1157-62. [PMID: 32772587 DOI: 10.1080/00365521.2020.1803397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Rieker L, Hofer J, Petzold G, Ellenrieder V, Amanzada A. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. BMC Gastroenterol 2022;22:22. [PMID: 35033015 DOI: 10.1186/s12876-022-02094-3] [Reference Citation Analysis]
365 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
366 Sninsky J, Barnes EL. Medical Management of Aggressive Inflammatory Bowel Disease: When Is the Time to Cut Your (and the Patient's) Losses? J Laparoendosc Adv Surg Tech A 2021;31:905-10. [PMID: 34171979 DOI: 10.1089/lap.2021.0338] [Reference Citation Analysis]
367 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
368 Dahiya DS, Perisetti A, Kichloo A, Singh A, Goyal H, Rotundo L, Vennikandam M, Shaka H, Singh G, Singh J, Pisipati S, Al-Haddad M, Sanaka MR, Inamdar S. Increasing thirty-day readmissions of Crohn’s disease and ulcerative colitis in the United States: A national dilemma. World J Gastrointest Pathophysiol 2022; 13(3): 85-95 [DOI: 10.4291/wjgp.v13.i3.85] [Reference Citation Analysis]
369 Mak JWY, Yuen NTK, Yip TCF, Lam RHM, Lam BKH, Cheng CTY, Wong GLH, Chan FKL, Ng SC. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. J Gastroenterol Hepatol 2022. [PMID: 35338526 DOI: 10.1111/jgh.15838] [Reference Citation Analysis]
370 Kousgaard SJ, Nielsen HL, Kirk KF, Thorlacius-Ussing O. Consumption of yoghurt favours remission after faecal microbiota transplantation for chronic pouchitis. Int J Colorectal Dis 2020;35:1955-8. [PMID: 32504332 DOI: 10.1007/s00384-020-03648-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
371 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
372 Wu Z, Bi Y. Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients. J Clin Lab Anal 2022;:e24130. [PMID: 34997981 DOI: 10.1002/jcla.24130] [Reference Citation Analysis]
373 Correia JP, Ponte AI, Silva JC, Gomes AC, Afecto E. Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:595. [PMID: 33657605 DOI: 10.1097/MEG.0000000000001901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Byrne LW, McKay D. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review. Surgeon 2021;19:e153-67. [PMID: 34581275 DOI: 10.1016/j.surge.2020.09.001] [Reference Citation Analysis]
375 Chugh R, Gaidos JK. Fertility and Pregnancy in Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.012] [Reference Citation Analysis]
376 Hagihara K, Mori R, Sekido Y, Ogino T, Hata T, Takahashi H, Miyoshi N, Uemura M, Doki Y, Eguchi H, Mizushima T. Defecation Function After Laparo-Assisted Restorative Proctocolectomy with Ileal Pouch Anal Anastomosis for Ulcerative Colitis. J Laparoendosc Adv Surg Tech A 2021. [PMID: 34569880 DOI: 10.1089/lap.2021.0465] [Reference Citation Analysis]
377 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Reference Citation Analysis]
378 Jena A, Mishra S, Singh AK, Sekar A, Sharma V. Cytomegalovirus in ulcerative colitis: An evidence-based approach to diagnosis and treatment. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032662] [Reference Citation Analysis]
379 Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE, Lindsay JO, Vega R, Thomas-Gibson S, Warusavitarne J, Wilson A, Graham TA, Hart A; Oxford IBD Cohort Study Investigators. Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. Gut 2021:gutjnl-2020-323546. [PMID: 33990383 DOI: 10.1136/gutjnl-2020-323546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Cao Y, Wang Z, Yan Y, Ji L, He J, Xuan B, Shen C, Ma Y, Jiang S, Ma D, Tong T, Zhang X, Gao Z, Zhu X, Fang J, Chen H, Hong J. Enterotoxigenic Bacteroides fragilis promotes intestinal inflammation and malignancy by inhibiting exosomes-packaged miR-149-3p. Gastroenterology 2021:S0016-5085(21)03341-2. [PMID: 34371001 DOI: 10.1053/j.gastro.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
381 Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm (2020) 2021;2:618-53. [PMID: 34977871 DOI: 10.1002/mco2.104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Irving PM, de Lusignan S, Tang D, Nijher M, Barrett K. Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study. BMJ Open Gastroenterol 2021;8:e000573. [PMID: 33597152 DOI: 10.1136/bmjgast-2020-000573] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2021;33:346-57. [PMID: 32889976 DOI: 10.1097/MEG.0000000000001917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
384 Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, Gras-Champel V, Masmoudi K, Bennis Y, Batteux B. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol 2021. [PMID: 33973280 DOI: 10.1111/fcp.12695] [Reference Citation Analysis]
385 Deputy M, Segal J, Reza L, Worley G, Costello S, Burns E, Faiz O, Clark S, Hart A. The pouch behaving badly: management of morbidity after ileal pouch-anal anastomosis. Colorectal Dis 2021;23:1193-204. [PMID: 33523546 DOI: 10.1111/codi.15553] [Reference Citation Analysis]
386 Kim MJ, Ko JS, Shin M, Hahn JW, Moon SY, Kim HY, Moon JS. Colorectal Cancer associated with pediatric inflammatory bowel disease: a case series. BMC Pediatr 2021;21:504. [PMID: 34763671 DOI: 10.1186/s12887-021-02966-9] [Reference Citation Analysis]
387 Hawthorne TZ, Shellien R, Chambers L, Devereux G. CMV pneumonitis in a patient with Crohn's disease taking azathioprine. BMJ Case Rep 2021;14:e241256. [PMID: 33893128 DOI: 10.1136/bcr-2020-241256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Choi YI, Kim YJ, Chung JW, Kim KO, Kim H, Park RW, Park DK. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform 2020;8:e15124. [PMID: 32293578 DOI: 10.2196/15124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
389 Braithwaite E, Carbonell J, Kane JS, Gracie D, Selinger CP. Patients' perception of colonoscopy and acceptance of colonoscopy based IBD related colorectal cancer surveillance. Expert Rev Gastroenterol Hepatol 2021;15:211-6. [PMID: 32981385 DOI: 10.1080/17474124.2021.1829971] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Akbar A, Orchard T, Powell N, Selinger C, tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101995] [Reference Citation Analysis]
391 Singhi AD, Waters KM, Makhoul EP, Parian A, Lazarev MG, Proksell SS, Dueker JM, Schwartz MB, Wald AI, Nikiforova MN, Montgomery EA. Targeted next-generation sequencing supports serrated epithelial change as an early precursor to inflammatory bowel disease-associated colorectal neoplasia. Hum Pathol 2021;112:9-19. [PMID: 33727167 DOI: 10.1016/j.humpath.2021.03.002] [Reference Citation Analysis]
392 Mintz MJ, Ananthakrishnan AN. Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. Inflamm Bowel Dis 2021;27:469-75. [PMID: 32430501 DOI: 10.1093/ibd/izaa094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Kapasi R, Glatter J, Lamb CA, Acheson AG, Andrews C, Arnott ID, Barrett KJ, Bell G, Bhatnagar G, Bloom S, Brookes MJ, Brown SR, Burch N, Burman A, Crook K, Cummings JF, Davies J, Demick A, Epstein J, Faiz O, Feakins R, Fletcher M, Garrick V, Jaffray B, Johnson M, Keetarut K, Limdi J, Meade U, Muhammed R, Murdock A, Posford N, Rowse G, Shaw I, St Clair Jones A, Taylor S, Weaver S, Younge L, Hawthorne AB. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterol 2020;11:178-87. [PMID: 32419908 DOI: 10.1136/flgastro-2019-101260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
394 Garrido I, Lopes S, Macedo G. Inflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic. Inflamm Bowel Dis 2020;26:e114-5. [PMID: 32737966 DOI: 10.1093/ibd/izaa204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
395 Arkteg CB, Wergeland Sørbye S, Buhl Riis L, Dalen SM, Florholmen J, Goll R. Real-life evaluation of histologic scores for Ulcerative Colitis in remission. PLoS One 2021;16:e0248224. [PMID: 33684168 DOI: 10.1371/journal.pone.0248224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Spencer NJ, Fryer AA, Farmer AD, Duff CJ. Blood test monitoring of immunomodulatory therapy in inflammatory disease. BMJ. [DOI: 10.1136/bmj.n159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
398 Meijboom RW, Gardarsdottir H, Becker ML, de Groot MCH, Movig KLL, Kuijvenhoven J, Egberts TCG, Leufkens HGM, Giezen TJ. Switching TNFα inhibitors: Patterns and determinants. Pharmacol Res Perspect 2021;9:e00843. [PMID: 34302442 DOI: 10.1002/prp2.843] [Reference Citation Analysis]
399 Ferenczi S, Solymosi N, Horváth I, Szeőcs N, Grózer Z, Kuti D, Juhász B, Winkler Z, Pankotai T, Sükösd F, Stágel A, Paholcsek M, Dóra D, Nagy N, Kovács KJ, Zanoni I, Szallasi Z. Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria. Mol Ther Methods Clin Dev 2021;20:218-26. [PMID: 33426148 DOI: 10.1016/j.omtm.2020.11.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, Garcia V, Sempere J. Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. World J Gastroenterol 2022; 28(5): 502-516 [DOI: 10.3748/wjg.v28.i5.502] [Reference Citation Analysis]
401 Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol. 2020;33:591-602. [PMID: 33162736 DOI: 10.20524/aog.2020.0547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
402 Iyer N, Corr SC. Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease. Nutrients 2021;13:4259. [PMID: 34959809 DOI: 10.3390/nu13124259] [Reference Citation Analysis]
403 Westberg K, Olén O, Söderling J, Bengtsson J, Ludvigsson JF, Everhov ÅH, Myrelid P, Nordenvall C. Primary Versus Staged Reconstruction and Risk of Surgical Failure in Patients With Ulcerative Colitis: a Nation-wide Cohort Study. Inflamm Bowel Dis 2021:izab263. [PMID: 34792582 DOI: 10.1093/ibd/izab263] [Reference Citation Analysis]
404 Lindhagen S, Karling P. A more frequent disease monitorering but no increased disease activity in patients with inflammatory bowel disease during the first year of the SARS-CoV-2 pandemic. A retrospective study. Scand J Gastroenterol 2021;:1-6. [PMID: 34699290 DOI: 10.1080/00365521.2021.1993328] [Reference Citation Analysis]
405 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
406 Argüelles-arias F, Bermejo F, Borrás-blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086131] [Reference Citation Analysis]
407 Soop M. Challenges in Crohn's disease: Intestinal failure and short bowel syndrome in Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100749. [DOI: 10.1016/j.scrs.2020.100749] [Reference Citation Analysis]
408 Long Y, Zhao X, Liu C, Xia C, Liu C. Activated inducible co-stimulator-positive programmed cell death 1-positive follicular helper T cells indicate disease activity and severity in ulcerative colitis patients. Clin Exp Immunol 2020;202:106-18. [PMID: 32621310 DOI: 10.1111/cei.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
409 Soop M, Khan H, Nixon E, Teubner A, Abraham A, Carlson G, Lal S. Causes and Prognosis of Intestinal Failure in Crohn's Disease: An 18-year Experience From a National Centre. J Crohns Colitis. 2020;14:1558-1564. [PMID: 32215559 DOI: 10.1093/ecco-jcc/jjaa060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Di Ruscio M, Tinazzi I, Variola A, Geccherle A, Marchetta A, McGonagle D. Prevalence and Real-World Management of Vedolizumab Associated Enthesitis in Successfully Treated IBD Patients. Rheumatology (Oxford) 2021:keab135. [PMID: 33580246 DOI: 10.1093/rheumatology/keab135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Hart A, Ng SC, Watkins J, Paridaens K, Edwards JO, Fullarton JR, Sonderegger YLY, Ghatnekar O, Ghosh S. The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol 2020;33:500-7. [PMID: 32879597 DOI: 10.20524/aog.2020.0521] [Reference Citation Analysis]
413 Huang X, Liu F, Guan H, Jiang Z, Wei P, Luo Y, Jia Q. Effects of endoscopic submucosal dissection on post-operative early treatment effectiveness and serum TAT-2 and GP73 expression levels in patients with early gastric cancer. Exp Ther Med 2021;22:806. [PMID: 34093762 DOI: 10.3892/etm.2021.10238] [Reference Citation Analysis]
414 Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol 2021; 27(28): 4504-4535 [PMID: 34366621 DOI: 10.3748/wjg.v27.i28.4504] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Mehta P, Manson JJ. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? Front Immunol 2020;11:589. [PMID: 32318070 DOI: 10.3389/fimmu.2020.00589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
416 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
417 Keung C, Heraud P, Kuk N, Lim R, Sievert W, Moore G, Wood B. Fourier-Transform Infra-Red Microspectroscopy Can Accurately Diagnose Colitis and Assess Severity of Inflammation. IJMS 2022;23:2849. [DOI: 10.3390/ijms23052849] [Reference Citation Analysis]
418 Zhang Z, Hyun JE, Thiesen A, Park H, Hotte N, Watanabe H, Higashiyama T, Madsen KL. Sex-Specific Differences in the Gut Microbiome in Response to Dietary Fiber Supplementation in IL-10-Deficient Mice. Nutrients 2020;12:E2088. [PMID: 32679670 DOI: 10.3390/nu12072088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Wickramasekera N, Coates E, Barr A, Lee MJ, Blackwell S, Bedford H, Dames N, Sebastian S, Probert C, Shackley P, Lobo AJ. Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment. Scand J Gastroenterol 2022;:1-10. [PMID: 35142585 DOI: 10.1080/00365521.2022.2036808] [Reference Citation Analysis]
420 Gibson DJ, Doherty GA. Fast and Curious: An Algorithmic Approach to Infliximab Dosing in Acute Severe Ulcerative Colitis. Dig Dis Sci 2020;65:1584-5. [PMID: 31970607 DOI: 10.1007/s10620-020-06084-x] [Reference Citation Analysis]
421 Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, Lamas-Díaz MJ. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021;87:2216-27. [PMID: 33197071 DOI: 10.1111/bcp.14654] [Reference Citation Analysis]
422 Zielińska A, Sobolewska-Włodarczyk A, Wiśniewska-Jarosińska M, Gąsiorowska A, Fichna J, Sałaga M. The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency. Pharmaceuticals (Basel) 2021;14:284. [PMID: 33809912 DOI: 10.3390/ph14030284] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
424 Fasoulas K, Stergiou E, Soufleris K. Ustekinumab for Crohn Disease With Severe Gastroduodenal Involvement. Inflamm Bowel Dis 2021:izab128. [PMID: 33999143 DOI: 10.1093/ibd/izab128] [Reference Citation Analysis]
425 Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, Alexakis C, Pollok RC. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. Journal of Crohn's and Colitis 2021;15:203-11. [DOI: 10.1093/ecco-jcc/jjaa146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
426 Snell A, Segal J, Limdi J, Banerjee R. Inflammatory bowel disease in India: challenges and opportunities. Frontline Gastroenterol 2021;12:390-6. [DOI: 10.1136/flgastro-2020-101500] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Kichloo A, Dahiya DS, Shaka H, Jamal S, Khan MZ, Wani F, Mehboob A, Kanjwal K. Impact of atrial fibrillation on inflammatory bowel disease hospitalizations-a nationwide retrospective study. Proc (Bayl Univ Med Cent) 2021;34:673-7. [PMID: 34732983 DOI: 10.1080/08998280.2021.1951071] [Reference Citation Analysis]
428 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
429 Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev 2021;1:CD013529. [PMID: 33471939 DOI: 10.1002/14651858.CD013529.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
430 Dore MP, Fanciulli G, Manca A, Cocco V, Nieddu A, Murgia M, Pes GM. Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study. Scand J Gastroenterol 2021;56:171-6. [PMID: 33327797 DOI: 10.1080/00365521.2020.1861323] [Reference Citation Analysis]
431 O'Hagan P, Limdi J, Akbar A, Tucknott S, Kahol DN. Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients. Curr Med Res Opin 2021;37:1901-11. [PMID: 34420463 DOI: 10.1080/03007995.2021.1971180] [Reference Citation Analysis]
432 Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021;326:2375-84. [PMID: 34932077 DOI: 10.1001/jama.2021.21316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Reference Citation Analysis]
434 Nuñez F P, Quera R, Simian D, Flores L, Figueroa C, Ibañez P, Kronberg U, Lubascher J, Pizarro G. Infliximab in inflammatory bowel disease. Is premedication necessary? Gastroenterol Hepatol 2021;44:321-9. [PMID: 33386199 DOI: 10.1016/j.gastrohep.2020.07.018] [Reference Citation Analysis]
435 Jiang P, Lai S, Wu S, Zhao XM, Chen WH. Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment. BMC Genomics 2020;21:348. [PMID: 32393180 DOI: 10.1186/s12864-020-6749-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
436 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2021:izab299. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
437 Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol 2021;15:891-908. [PMID: 34148466 DOI: 10.1080/17474124.2021.1940956] [Reference Citation Analysis]
438 Toyonaga T, Steinbach EC, Keith BP, Barrow JB, Schaner MR, Wolber EA, Beasley C, Huling J, Wang Y, Allbritton NL, Chaumont N, Sadiq TS, Koruda MJ, Jain A, Long MD, Barnes EL, Herfarth HH, Isaacs KL, Hansen JJ, Shanahan MT, Rahbar R, Furey TS, Sethupathy P, Sheikh SZ. Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cell Mol Gastroenterol Hepatol 2020;10:779-96. [PMID: 32561494 DOI: 10.1016/j.jcmgh.2020.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
439 Gatenby G, Glyn T, Pearson J, Gearry R, Eglinton T. The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. Colorectal Dis 2021. [PMID: 34041848 DOI: 10.1111/codi.15756] [Reference Citation Analysis]
440 Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Front Immunol 2021;12:691480. [DOI: 10.3389/fimmu.2021.691480] [Reference Citation Analysis]
441 Lamberg T, Sipponen T, Valtanen S, Eklund KK, Mälkönen T, Aalto K, Mikola K, Kolho KL, Leinonen S, Isomäki P, Mäkinen H, Vidqvist KL, Kokko A, Huilaja L, Kyllönen M, Keskitalo P, Sard S, Vähäsalo P, Koskela R, Kröger L, Lahtinen P, Haapala AM, Korkatti K, Sokka-Isler T, Jokiranta TS; BLING Research Group. Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases. Autoimmunity 2022;:1-10. [PMID: 35481450 DOI: 10.1080/08916934.2022.2067985] [Reference Citation Analysis]
442 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
443 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Reference Citation Analysis]
444 Colombo A, Giuffrè M, Crocè LS, Venturini S, Sablich R. Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test. Pathogens 2021;10:535. [PMID: 33946817 DOI: 10.3390/pathogens10050535] [Reference Citation Analysis]
445 Crooks B, Mclaughlin J, Limdi J. Dietary beliefs and recommendations in inflammatory bowel disease: a national survey of healthcare professionals in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2020-101723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]